GleamWall
中文EN

SXTC China SXT Pharmaceuticals, Inc. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1723980 · Fiscal year ends 03/31

Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-34.6%
TTM net income YoY-87.8%
TTM EPS YoY97.4%
Revenue 3-yr CAGR-16.7%
Net income 3-yr CAGR—

Margins

Gross margin21.9%
Operating margin-625.9%
Net margin-545.2%
FCF margin—
EBITDA margin-619.4%

Returns

ROE-27.5%
ROA-22.0%
ROIC (approx.)—
Asset turnover0.04x

Leverage & solvency

Liabilities / assets14.5%
Debt / equity0.03x
Current ratio7.93x
Interest coverage-113.13x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-7.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20262026-03-31FY20252025-03-31
Income statement
Revenue$1.14M$1.74M
Cost of revenue$889,350$1.37M
Gross profit$248,702$367,427
SG&A expense$7.13M$2.76M
Operating income-$7.12M-$2.68M
Interest expense$62,965$648,221
Pretax income-$6.21M-$3.30M
Net income-$6.21M-$3.30M
EBITDA-$7.05M-$2.60M
EPS (basic)-9.13-348.17
EPS (diluted)-9.13-348.17
Weighted avg. shares (diluted)679,6489,489
Banking
Deposits—$7.27M
Balance sheet
Cash & equivalents$28.18M$18.10M
Receivables$931,567$1.30M
Inventory$777,059$828,053
Current assets$34.51M$21.30M
PP&E, net$117,103$178,561
Intangibles$6,328$11,808
Total assets$34.75M$21.66M
Current liabilities$4.35M$6.01M
Short-term debt$355,175$8,781
Long-term debt$644,390$96,264
Total debt$999,565$105,045
Total liabilities$5.05M$6.22M
Shareholders' equity$29.71M$15.44M
Net debt-$27.18M-$17.99M
Shares outstanding—91,756
Cash flow statement
Operating cash flow-$4.02M-$2.35M
Capital expenditure—$2,023
Free cash flow—-$2.35M
Investing cash flow-$1.25M$63,516
Financing cash flow$14.43M$8.40M
Depreciation & amortization$73,668$82,297
Stock-based compensation$5.31M—

Free plan shows the latest 2 periods; Pro shows all 10 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.